The 6th BioCentury-BayHelix East-West Biopharma Summit Returns to Seoul Amid Unprecedented Demand for Cross-Border Deals

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire The 6th BioCentury-BayHelix East-West Biopharma Summit Returns to Seoul Amid Unprecedented Demand for Cross-Border DealsAuthor of the article:THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountRegistration is open for the 6th BioCentury- BayHelix East-West Biopharma Summit, whose Regional Host Chair represents about 300 Korean pharmaceutical and biotech companies. Join BioCentury, BayHelix, and KPBMA in Seoul, March 15-17, 2027SEOUL, South Korea — BioCentury today announced that the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) will serve as Regional Host Chair of the 6th BioCentury-BayHelix East-West Biopharma Summit, taking place March 15-17, 2027, at the Conrad Seoul in South Korea. Presented by BioCentury, BayHelix, and Insights Partner McKinsey & Company, the East-West Biopharma Summit returns to Seoul for the second time to continue the debate on Asia’s Arc of Innovation, with KPBMA helping connect Korea’s biopharma leaders with investors and dealmakers from across Asia and the West.This advertisement has not loaded yet, but your article continues below.KPBMA President Yunhong Noh chairs the East-West Biopharma Summit’s Regional Host Committee, which brings together senior leaders from across Korea’s biopharma ecosystem, including executives from ABL Bio, Alteogen, CHA Biotech, Ildong Pharmaceutical, KB Investments, the Korea Health Industry Development Institute, LG Chem, and SK Biopharmaceuticals. The committee works alongside the East-West Biopharma Summit’s International Steering Committee to shape a program built around Korea’s growing role as a source of first-in-class innovation and a destination of choice for clinical trials and biomanufacturing.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“Korean companies have advanced first-in-class science, strong clinical infrastructure, and biomanufacturing capabilities at global scale. The next step is sustained access to the investors and partners who can help bring these innovations to patients worldwide. Bringing the East-West Biopharma Summit to Seoul connects our members directly with global investors and industry leaders, creating opportunities for meaningful partnerships. We believe the Summit will catalyze new cross-border partnerships that drive innovation and further strengthen K-Pharma’s position in the global biopharma landscape,” said Yunhong Noh, President of KPBMA and Chairman of the Summit’s Regional Host Committee.The East-West Biopharma Summit offers C-level networking, partnering, and debate for VCs, private equity investors, biotech CEOs, CFOs, and CBOs, and business development and licensing leaders from Australia, China, India, Japan, Singapore, South Korea, Southeast Asia, and the West. The East-West Biopharma Summit’s agenda sessions will examine:How leading Asia biotechs are generating faster clinical data to advance their pipelines and derisk global developmentHow global partners can source assets for worldwide markets from emerging innovation hubs across Asia’s Arc of InnovationWhich Asia-originated assets investors and BD&L leaders see as most compelling for licensing and NewCo creationWhich Asia-based contract development and manufacturing organizations and service providers are best positioned to accelerate global pipelinesWhere licensing and NewCo opportunities are emerging in Korea, Japan, Singapore, Australia, and other Asia marketsDelegates can also see Korea’s ecosystem firsthand. The program includes an ecosystem tour on the morning of March 15 and an overnight excursion March 17-18 to Songdo, home to Samsung Biologics, Celltrion, and Lotte Biologics. An exclusive CEO and Investor Reception on March 15 adds further networking. Space on the tours and at the reception is limited, and early registration is encouraged.This advertisement has not loaded yet, but your article continues below.“Seoul is a natural home for the East-West Biopharma Summit. Korean companies are among the most active partners in cross-border dealmaking today, bringing innovative science, deep clinical expertise, and world-class manufacturing to the table. Returning with KPBMA as our Regional Host Chair lets us connect global investors and pharma executives with the leaders behind that momentum, in the city where so much of it is happening,” said David Flores, Co-Founder, President and CEO of BioCentury.Registration for the 6th BioCentury-BayHelix East-West Biopharma Summit is open on the East-West Biopharma Summit registration site. Biotechs from Korea, Asia, and the West can apply to join the Presenting Company Class of 2027 to pitch to potential investors and partners, and organizations interested in thought leadership and branding can review sponsorship opportunities.BioCentury is the preeminent biopharma intelligence and networking platform, trusted as the gold standard by biotech and pharma executives, investors, thought leaders, and policymakers. For over 30 years, we have created a view beyond the horizon — supporting the creation of transformational medicines for patients and enabling biotech leaders to understand what’s coming next.Since its founding in 1945, KPBMA has represented Korea’s pharmaceutical and biopharma industry. Its membership of about 300 companies spans pharmaceutical manufacturers, R&D-driven biotechs, and innovators in digital transformation and AI, and the association works with bio clusters and industry networks to support cross-border investment and pipeline collaboration between Korean companies and international partners.View source version on businesswire.com: BioCentury, Inc.Michael Kelly | Senior Marketing Manager, Event Growth & Demand Strategyconferences@biocentury.comThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.